- Home
- SABR vs SLN Comparison
SABR vs SLN Comparison
Compare SABR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | SLN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.2M | 678.0M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SABR | SLN |
|---|---|---|
| Price | $1.81 | $8.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $2.11 | ★ $33.00 |
| AVG Volume (30 Days) | ★ 5.8M | 879.4K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,866,956,000.00 | $559,000.00 |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $4.16 | $130.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $4.19 |
| 52 Week High | $2.50 | $17.58 |
Technical Indicators
Market Signals| Indicator | SABR | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 23.89 |
| Support Level | $1.68 | $4.70 |
| Resistance Level | $1.99 | $11.06 |
| Average True Range (ATR) | 0.09 | 0.58 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 16.04 | 9.53 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.